Harnessing the power of urinary miRNA to detect cancer early

Improving Health Outcomes through
Early Detection 

Detecting cancers in early stages when it is treatable

TECHNOLOGY

Targeting microRNA to improve early detection

Craif has harnessed the power of miRNA in cancer pathways to detect cancer in early stages when it is still treatable. Our primary focus is pancreatic cancer, which today is often detected too late to save lives.

READ MORE ABOUT OUR SCIENCE

PRODUCT

Multi-cancer Early Detection Urine Test available in Japan

miSignal test can detect 7 types of cancer (pancreatic, colorectal, lung, stomach, esophagus breast, ovarian) from a simple urine draw.* available in Japan

USA TEAM

Experienced USA Team with Proven Track Record

Kristine Mechem PhD

Kristine Mechem PhD

Chief Corporate Development Officer
US Lead

20 years Life Science experience across diagnostics, medical devices and biopharma with lead or key player in six product launch teams including 11 years in diagnostics with roles Officer/Head of Commercial for early cancer detection assay, practice leader  Precision Medicine at Health Advances working with molecular diagnostic companies in launch planning and pipeline prioritization, Business Development lead for early stage maternal fetal health diagnostic.

Lyssa Friedman

Lyssa Friedman

Head of Clinical Operations (Consultant)

Clinical operations executive with over 15 years experience leading IVD and medical device clinical operations teams. Co-author of peer-reviewed publications that have driven successful product launches and positive payer decisions.

Josh Cottrell

Josh Cottrell

Head of Program Management (Consultant)

Accomplished leader with over 20 years of assay, software, device, and systems IVD experience from R&D and validation through clinical trials, regulatory filings, commercialization, and audits (FDA and CE).

Bill Haack

Bill Haack

Head of Market Access

25+ years of experience in the life sciences industry, primarily as a commercial and market access executive including commercial operations leader at Genentech where he helped launch Rituxan, Herceptin and Avastin and one of the first employees at Genomic Health where he led the reimbursement effort and helped grow annual revenues to over $300M.

Martina Doleshal

Martina Doleshal

Head of Market Planning

Strategic business leader with over 19+ years of demonstrated expertise in innovation, strategy development, and market planning. Successfully launched novel healthcare products into global markets and diverse regulatory environments for startups and Fortune 500 companies.

Lyndal Hesterberg PhD

Lyndal Hesterberg PhD

Advisor providing regulatory and compliance support for US product development

Successfully guided the establishment of multiple licensed CLIA Labs and the Verification/Validation of multiple LDT clinical diagnostics including multiple analyte algorithm based tests.

NEWS